CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Explore Blueprint Medicines's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 7, 2025
Patent NumberGrant DateTitleTotal Oppositions
Nov 1, 2023Ret Inhibitor For Use In Treating Cancer Having A Ret Alteration1
Sep 6, 2023Crystalline Forms Of (S)-1-(4-Fluorophenyl)-1-(2-(4-(6-(1-Methyl-1H-Pyrazol-4-Yl)Pyrrolo[2,1-F][1,2,4]Triazin-4-Yl)Piperazinyl)-Pyrimidin-5-Yl)Ethan-1-Amine And Methods Of Making1

Top competitors of Blueprint Medicines

List of top competitors of Blueprint Medicines based on patent oppositions.